Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
This is the feed from
CNBC - Healthcare
Is this your feed? Claim it!
Publisher: Unclaimed!
Message frequency: 1.32 / day
Message History
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.